All three new drugs are approved for atrial fibrillation treatment in people who do not have heart valve problems or artificial valves. One of the three also has FDA approval for additional conditions.
Atrial fibrillation disrupts the flow of blood through the heart. As blood pools, it's more likely to form clots that can travel to the brain, causing a stroke.
The new drugs are different in some respects but work in the same general way. ''All of them work on the clotting 'cascade,'" says John Doherty, MD. He is a professor of medicine at the Thomas Jefferson University School of Medicine, Philadelphia, and a member of the American College of Cardiology's Anticoagulation Initiative.
That cascade ''is a series of events by which different compounds are generated and ultimately result in blood coagulation [clotting]."
The three new drugs, which target various points along that cascade, include:
Pradaxa (dabigatran).It was approved by the FDA in October 2010 for prevention of stroke and blood clots in people with atrial fibrillation.
Xarelto (rivaroxaban). It was approved in November 2011 to prevent a stroke from atrial fibrillation. It had been approved earlier to lower the risk of blood clots after hip and knee replacements.
In November 2012, the FDA also approved it to treat deep vein thrombosis, (blood clots that occur usually in the lower leg and thigh) and pulmonary embolism (the condition that results when a blood clot from a vein breaks off and travels to an artery in the lungs and blocks blood flow.)